Ocular Therapeutix reports positive 12-month Phase 1 data for OTX-TKI in wet AMD

OCULAR THERAPEUTIX, INC

12-month data showed OTX-TKI maintained controlled wet AMD comparable to aflibercept, with mean BCVA change of -1.0 letters vs +2.0 letters.
89% reduction in treatment burden observed in OTX-TKI subjects at 12 months; 60% were rescue-free up to Month 12.
No drug-related ocular or systemic serious adverse events in OTX-TKI arm; one SAE of endophthalmitis related to injection procedure.
Company plans to initiate a pivotal trial in wet AMD as early as Q3 2023, subject to obtaining necessary financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.